These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 23840612)

  • 1. Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease.
    Alisi A; Ceccarelli S; Panera N; Prono F; Petrini S; De Stefanis C; Pezzullo M; Tozzi A; Villani A; Bedogni G; Nobili V
    PLoS One; 2013; 8(6):e67160. PubMed ID: 23840612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FGF19 and FGF21 for the Treatment of NASH-Two Sides of the Same Coin? Differential and Overlapping Effects of FGF19 and FGF21 From Mice to Human.
    Henriksson E; Andersen B
    Front Endocrinol (Lausanne); 2020; 11():601349. PubMed ID: 33414764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma Fibroblast Growth Factor 21 Is Associated With Severity of Nonalcoholic Steatohepatitis in Patients With Obesity and Type 2 Diabetes.
    Barb D; Bril F; Kalavalapalli S; Cusi K
    J Clin Endocrinol Metab; 2019 Aug; 104(8):3327-3336. PubMed ID: 30848827
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatic farnesoid X receptor protein level and circulating fibroblast growth factor 19 concentration in children with NAFLD.
    Nobili V; Alisi A; Mosca A; Della Corte C; Veraldi S; De Vito R; De Stefanis C; D'Oria V; Jahnel J; Zohrer E; Scorletti E; Byrne CD
    Liver Int; 2018 Feb; 38(2):342-349. PubMed ID: 28746779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. β-Klotho gene variation is associated with liver damage in children with NAFLD.
    Dongiovanni P; Crudele A; Panera N; Romito I; Meroni M; De Stefanis C; Palma A; Comparcola D; Fracanzani AL; Miele L; Valenti L; Nobili V; Alisi A
    J Hepatol; 2020 Mar; 72(3):411-419. PubMed ID: 31655133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined Therapy with a CCR2/CCR5 Antagonist and FGF21 Analogue Synergizes in Ameliorating Steatohepatitis and Fibrosis.
    Puengel T; Lefere S; Hundertmark J; Kohlhepp M; Penners C; Van de Velde F; Lapauw B; Hoorens A; Devisscher L; Geerts A; Boehm S; Zhao Q; Krupinski J; Charles ED; Zinker B; Tacke F
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743140
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Klotho and fibroblast growth factors 19 and 21 serum concentrations in children and adolescents with normal body weight and obesity and their associations with metabolic parameters.
    Socha-Banasiak A; Michalak A; Pacześ K; Gaj Z; Fendler W; Socha A; Głowacka E; Kapka K; Gołąbek V; Czkwianianc E
    BMC Pediatr; 2020 Jun; 20(1):294. PubMed ID: 32546231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-alcoholic fatty liver disease is associated with dysregulated bile acid synthesis and diarrhea: A prospective observational study.
    Appleby RN; Moghul I; Khan S; Yee M; Manousou P; Neal TD; Walters JRF
    PLoS One; 2019; 14(1):e0211348. PubMed ID: 30682184
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fibroblast growth factor 21 in non-alcoholic fatty liver disease.
    Tucker B; Li H; Long X; Rye KA; Ong KL
    Metabolism; 2019 Dec; 101():153994. PubMed ID: 31672443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response of fibroblast growth factor 19 and bile acid synthesis after a body weight-adjusted oral fat tolerance test in overweight and obese NAFLD patients: a non-randomized controlled pilot trial.
    Friedrich D; Marschall HU; Lammert F
    BMC Gastroenterol; 2018 Jun; 18(1):76. PubMed ID: 29866129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Biological and pharmacological functions of the FGF19- and FGF21-coreceptor beta klotho.
    Aaldijk AS; Verzijl CRC; Jonker JW; Struik D
    Front Endocrinol (Lausanne); 2023; 14():1150222. PubMed ID: 37260446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fibroblast Growth Factors for Nonalcoholic Fatty Liver Disease: Opportunities and Challenges.
    Tian H; Zhang S; Liu Y; Wu Y; Zhang D
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36902015
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of Fibroblast Growth Factor 21 and β-Klotho Regulates Hepatic Fibrosis through the Nuclear Factor-κB and c-Jun N-Terminal Kinase Pathways.
    Lee KJ; Jang YO; Cha SK; Kim MY; Park KS; Eom YW; Baik SK
    Gut Liver; 2018 Jul; 12(4):449-456. PubMed ID: 29699061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Opposite alterations in FGF21 and FGF19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients.
    Gallego-Escuredo JM; Gómez-Ambrosi J; Catalan V; Domingo P; Giralt M; Frühbeck G; Villarroya F
    Int J Obes (Lond); 2015 Jan; 39(1):121-9. PubMed ID: 24813368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibroblast growth factor-21 and omentin-1 hepatic mRNA expression and serum levels in morbidly obese women with non-alcoholic fatty liver disease.
    Waluga M; Kukla M; Zorniak M; Kajor M; Liszka L; Dyaczynski M; Kowalski G; Zadlo D; Waluga E; Olczyk P; Buldak RJ; Berdowska A; Hartleb M
    J Physiol Pharmacol; 2017 Jun; 68(3):363-374. PubMed ID: 28820393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting FGF21 for the Treatment of Nonalcoholic Steatohepatitis.
    Zarei M; Pizarro-Delgado J; Barroso E; Palomer X; Vázquez-Carrera M
    Trends Pharmacol Sci; 2020 Mar; 41(3):199-208. PubMed ID: 31980251
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Complementary Role of Fibroblast Growth Factor 21 and Cytokeratin 18 in Monitoring the Different Stages of Nonalcoholic Fatty Liver Disease.
    Wu G; Li H; Fang Q; Zhang J; Zhang M; Zhang L; Wu L; Hou X; Lu J; Bao Y; Jia W
    Sci Rep; 2017 Jul; 7(1):5095. PubMed ID: 28698650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum Fibroblast Growth Factor 21 Is Markedly Decreased following Exercise Training in Patients with Biopsy-Proven Nonalcoholic Steatohepatitis.
    Stine JG; Welles JE; Keating S; Hussaini Z; Soriano C; Heinle JW; Geyer N; Chinchilli VM; Loomba R; Kimball SR
    Nutrients; 2023 Mar; 15(6):. PubMed ID: 36986211
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum FGF21 increases with hepatic fat accumulation in pediatric onset intestinal failure.
    Mutanen A; Heikkilä P; Lohi J; Raivio T; Jalanko H; Pakarinen MP
    J Hepatol; 2014 Jan; 60(1):183-90. PubMed ID: 24021426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fibroblast growth factor 21 is a hepatokine involved in MASLD progression.
    Gallego-Durán R; Ampuero J; Maya-Miles D; Pastor-Ramírez H; Montero-Vallejo R; Rivera-Esteban J; Álvarez-Amor L; Pareja MJ; Rico MC; Millán R; Robles-Frías MJ; Aller R; Rojas Á; Muñoz-Hernández R; Gil-Gómez A; Gato S; García-Lozano M; Arias-Loste MT; Abad J; Calleja JL; Andrade RJ; Crespo J; González-Rodríguez Á; García-Monzón C; Andreola F; Pericás JM; Jalan R; Martín-Bermudo F; Romero-Gómez M
    United European Gastroenterol J; 2024 Oct; 12(8):1056-1068. PubMed ID: 38894596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.